Cirrus Networks kicks off reporting season with a solid 1HY23 result
Nick Sundich, February 2, 2023
IT services company Cirrus Networks (ASX:CNW) is one of the first companies to release its 1HY23 results. To say shareholders were impressed by the results would be an understatement, judging by this morning’s initial 23% share price jump.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Cirrus Networks is benefiting from strong demand for IT services
Cirrus Networks is a Managed Services Provider (MSP) that targets mid-market enterprises.
MSPs deliver IT services, such as network, application, infrastructure and security, via ongoing and regular support as well as active administration wherever the customer needs it.
Spending on IT services by Australian companies is expected to grow from $37bn in 2021 to $43.5bn in 2025, representing a CAGR of 4.1%.
Cirrus Networks (ASX:CNW) share price chart, log scale (Source: TradingView)
A good 1HY23 result
In 1HY23, Cirrus recorded $56.7m in revenue (up 27%), $2.2m in EBITDA (up from an $0.4m loss in 1HY22) and a $1.3m pre-tax profit (up from a $2.2m loss in 1HY22). The company closed the period with a healthy balance sheet, with $9.5m in cash and zero debt.
Cirrus Networks credited the market demand, its strong market position and more disciplined focus on overhead spend for its good results. It guided to a strong 2HY23 as well.
The company’s share rose by more 20% this morning, which bodes well for shareholders of other ASX companies that are anticipating solid results over the next few weeks.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Avita Medical (ASX:AVH): Will the FDA’s last minute Christmas present catapult it to new heights in 2025?
Avita Medical (ASX:AVH) received not one, but two Christmas presents from the FDA. On December 19, it announced 510(k) clearance…
Here are our 6 Best ASX Stocks for 2025 and why you should give them a look!
Here are our 6 Best ASX Stocks for 2025! Opthea (ASX:OPT) Its been a long wait, but 2025 will…
5 ASX stocks with the highest PE multiples and 5 ASX stocks with the lowest PE multiples!
5 ASX stocks with the highest PE multiples Note: All figures are in AUD and for FY25 unless otherwise stated…